



Classical to Current Approach for Treatment of Psoriasis: A Review

Download Article:



Download
(PDF 1,119.8 kb)

Authors: [Rahman, Mahfoozur](#); [Alam, Kainat](#); [Zaki Ahmad, Mohammad](#); [Gupta, Gaurav](#); [Afzal, Muhammad](#); [Akhter, Sohail](#); [Kazmi, Imran](#); [Jyoti](#); [Jalees Ahmad, Farhan](#); [Anwar, Firoz](#)

Source: [Endocrine, Metabolic & Immune Disorders-Drug Targets \(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders\)](#), Volume 12, Number 3, 2012, pp. 287-302(16)

Publisher: [Bentham Science Publishers](#)

DOI: <https://doi.org/10.2174/187153012802002901>



[previous article](#)



[view table of contents](#)



[ADD TO FAVOURITES](#)



Abstract



[References](#)



[Citations](#)



[Supplementary Data](#)

Psoriasis is a genetic predisposition with T-cell mediated autoimmune inflammatory skin disorder, characterized by cutaneous inflammation, increased epidermal proliferation, hyperkeratosis, angiogenesis, and abnormal keratinization that affects up to 2 – 3% of the population worldwide. Common therapies that are used for the treatment of psoriasis include topical, systemic, phototherapy, combination, herbal therapy and novel molecules. Topically used agents include Vit D, calcipotriol, corticosteroids, dithranol and retinoids etc. Systemically used agents include methotrexate and cyclosporine etc. Phototherapy includes UV-B, Psoralen plus ultraviolet therapy and excimer laser etc. These therapies have a number of potential problems, such as limited in efficacy, inconvenience, organ toxicity, carcinogenic and broadband immunosuppression. In natural treatment a variety of natural agents such as methanolic extracts of duzhong (*Eucommia ulmoides* Oliv.), yerba mate (*Ilex paraguariensis*), linseed oil, fish oil, and Indigo naturalis etc., that modulates T cell and cytokine action at various steps along with the pathogenic sequence have been developed. But till now there is no more in vivo, dose and its efficacy data has been established. Current therapy includes biologicals, small molecules inhibitor and enzyme inhibitors etc, which serve as novel therapeutic options for psoriasis treatment. All these avoid the side effects of the prebiologically developed systemic agents including hepatotoxicity, nephrotoxicity, and bone marrow suppression. Currently, Denilukin diftitox, Efalizumab, Alefacept, Ustekinumab and Etanercept are approved by the FDA, and others molecules are at clinical stage. Patents issued by the US office are also included in current psoriasis treatment scenario. In the United States, biologicals are widely used for moderate-to-severe psoriasis. But because of the high cost of medication and their availability in injection form, it remains to be seen how widely these agents will be utilized worldwide. Still, developing countries prefer conventional drugs.

Keywords: [Activator protein-1](#); [Arachidonic acid](#); [Cluster of differentiation molecule](#); [Conventional treatment](#); [Cyclooxygenase](#); [Docosahexaenoic acid](#); [Eicosapentaenoic acid](#); [Insulin-like Growth Factor 1](#); [genetic factor](#); [herbal drugs](#); [novel molecules](#); [patents](#); [psoriasis](#)









Document Type: Research Article

Publication date: September 1, 2012

› [More about this publication?](#)

Share Content

Access Key

-  Free content
-  Partial Free content
-  New content
-  Open access content
-  Partial Open access content
-  Subscribed content
-  Partial Subscribed content
-  Free trial content

[Browse by Publication](#)

[Browse by Subject](#)

[Browse by Publisher](#)

[Advanced Search](#)

[About us](#)

[Researchers](#)

[Librarians](#)

[New featured titles](#)

[Help](#)

[Contact us](#)



Website © 2024 Ingenta. Article copyright remains with the publisher, society or author(s) as specified within the article.

Ingenta is not the publisher of the publication content on this website. The responsibility for the publication content rests with the publishers providing the material. Please refer to our [Terms and Conditions](#).

[Terms and Conditions](#)

[Privacy](#)

[Information for Advertisers](#)

[Cookie Policy](#)